APP and Alzheimer disease: In AD models (APP/PS1), mesenchymal stem cells (MSCs) overexpressing CX3CL1 reduced TNF-α levels and upregulated synaptic proteins, though cognitive benefits were observed only when CX3CL1 was co-expressed with Wnt3a (Li et al., 2020).